Advertisement


Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

2023 ASCO Annual Meeting

Advertisement

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The optimal management of older patients with DLBCL remains unclear and is very variable from practice to practice. The most commonly used regimen for older patients with diffuse large B-cell lymphoma is a regimen called R-mini-CHOP, which is more or less a 50% dose reduction in the cumulative chemotherapy compared to a younger patient who gets R-CHOP21. At our institution, we have developed a regimen called split-dose R-CHOP, which basically fractionates R-CHOP21 into two half doses with full-dose rituximab given on day one, and a 50% dose reduction of the CHOP regimen on day one and day 15, so that a 28-day cycle of split-dose R-CHOP gave the same chemo cumulative dose of chemotherapy as R-CHOP21. We designed this study as a way to deliver the same dose intensity to older patients, but by fractionating it, making it more tolerable to a patient population that's at higher risk of the toxicities associated with chemotherapy. In addition, because older patients could benefit from a truncated chemotherapy regimen, we included an interim analysis of patients, where we looked at them using PET-CT and MRD, using a cell-free DNA assay- [inaudible 00:01:33]- ... to look at the depth of response after two months of split-dose R-CHOP. For those patients who are both MRD-negative and, by Deauville criteria, a PET score of one, two, or three, those patients were then offered an abbreviated chemotherapy arm where they would finish after four months of split-dose R-CHOP instead of six months. Here, we are presenting our interim feasibility endpoint, which was based on the end-of-treatment CR rate. We're reporting data on 14 patients who have completed treatment, and our end-of-CR rate with 71%, meeting our interim feasibility endpoint early with 10 of the 14 patients achieving a complete remission. Overall, this regimen was well-tolerated. There were adverse events as described in the data that we've shown, but some of these are to be expected treating an older patient population, but there were no treatment-related deaths directly related to the chemotherapy. The most interesting aspect of this data was, however, that analysis we did using PET-CT and MRD. For six patients, who were both MRD-negative and PET-CT-negative, five of the six went onto the abbreviated arm. Even though they finished this truncated regimen, all of them remained in remission to-date. This shows that there might be power in this early-responding group that have a high in-depth- [inaudible 00:03:03]- ... response of this early interim analysis. We look forward to sharing this data at ASCO, and continuing to enroll patients, but we think that this could become a paradigm on how to treat older patients with DLBCL using novel endpoints, while offering a regimen with the same dose intensity that we offer younger patients to improve efficacy.

Related Videos

Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the combination of erdafitinib and cetrelimab, which demonstrated clinically meaningful activity and was well tolerated in cisplatin-ineligible patients with metastatic urothelial carcinoma and fibroblast growth factor receptor alterations (Abstract 4504).

Breast Cancer

Jennifer A. Ligibel, MD, on Early Breast Cancer and Weight Loss: Results From the BWEL Trial

Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, discusses a telephone-based weight loss intervention that induced clinically meaningful weight loss in patients with breast cancer who had overweight and obesity, across demographic and tumor factors. Additional tailoring of the intervention may possibly enhance weight loss in Black and younger patients as well (Abstract 12001).

Skin Cancer
Immunotherapy

Omid Hamid, MD, on Advanced Melanoma: Durable Response With Fianlimab Plus Cemiplimab

Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).

Lymphoma

Tycel J. Phillips, MD, and Emanuele Zucca, MD, on Primary Mediastinal B-Cell Lymphoma: New Data on Observation vs Radiotherapy

Tycel J. Phillips, MD, of City of Hope National Medical Center, and Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and the International Extranodal Lymphoma Study Group, discuss findings from the largest prospective study of patients with primary mediastinal B-cell lymphoma. The trial data support omitting radiotherapy in patients who achieve complete metabolic response after immunochemotherapy (Abstract LBA7505).

Skin Cancer
Immunotherapy

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Adnan Khattak, MBBS, FRACP, PhD, of Australia’s Hollywood Private Hospital & Edith Cowan University, discuss the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone. These results provide further evidence that a personalized neoantigen approach is potentially beneficial (Abstract LBA9503).

Advertisement

Advertisement




Advertisement